Safety of endoscopic papillectomy after a pancreatic stent placement above the pancreatic duct orifice

Safety of endoscopic papillectomy after a pancreatic stent placement above the pancreatic duct orifice - Inside pancreatic stenting papillectomy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010389

Enrollment

Registered

2013-04-01

Start date

2012-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tumors of the major duodenal papilla

Interventions

Placement of pancreatic stent and endoscopic papillectomy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Protruded-type tumors of the major duodenal papilla 2) Lesion confined to the major duodenal papilla without spread into the bile duct or pancreatic duct 3) Patients who provided written informed consent

Exclusion criteria

Exclusion criteria: 1) Distant metastases to other organs and lymph nodes 2) Hemorrhagic tendency in patients receiving oral anticoagulants, those with hepatic cirrhosis with coagulation disorders 3) Possibility of the pregnancy 4) Patients who were judged inappropriate for the entry to this study by the investigators

Design outcomes

Primary

Measure	Time frame
Technical success rate Incidence of complications	—

Secondary

Measure	Time frame
Residual tumor rate Tumor recurrence rate	—

Countries

Japan

Contacts

Public ContactKazunari Nakahara

St. Marianna University School of Medicine Department of Gastroenterology and Hepatology

044-977-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026